Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is the news?
Good morning all: Glad to see SEVI is recovering well. Got some FLIP under .05 yesterday---a swing trade, not day trade. The CEO recently bought 5 million shares and I like that kind of insider buying.
Here is a risky one to consider: EYII Company announced a 210 million dollar contract in China and the Chinese gov.'t has held up the deal with red tape. May be about over and the CEO hinted last week that shipments could begin in this month or next. Hopefully it would jump about 7 or 8 cents on that. Risky--but fun.
Covad news today---an old fav. of mine. Symbol DVW
Still playing with VWKM, WRVN and TWOG
Rooting on my Kansas Jayhawks this weekend. Hopefully we will not get upset like last year from Bucknell--a school I had never heard of.
Glad to know that. Heading to the golf course my friends. Keep the stocks in the GREEN
I'm gambling on ya POKER
Just grabbed 2 million
SEVI closed up 50 percent today--on no news???
Watch AEMD today. In 2004 it went from .50 to $4.00 in one hour--it has that kind of movement ability. Look for news today after yesterdays presentation.
VYST makes a lot of bomb screening devices for stadiums and with all the news this weekend about possible attacks at NCAA tourney I am hoping investors connect the dots. I have a lot of VYST. Have a good weekend all.
Good Friday morning to all. Big golf day here in the sunny midwest, but here is my stock opinions for the day. I like FLIP under .04----EENT is looking inviting at these prices, .06. Waiting for ATVE to drop a little and get in the swing trade. Probably will hold off until it drops below .12. I guess everyone is liking CHMS this morning. How many shares do they have outstanding? They do have cash--I like that.
love the optimism.
How high you thinking???!!!
COVAD news---DVW is the symbol. I have loved this company for too long now. Even gave it to a nephew for Christmas. He will love it.
Glad to see something I own has some PR.
DNAG NEWS
Updated:2006-03-09 07:18:48
Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc.
Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 03/09/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company. DNAPrint entered into an agreement with Harvard in January 2006 to sponsor continued research based on the marker, CD59, in the Harvard Medical School laboratory of Dr. Jose Halperin, a named inventor of the allowed claims. These claims, once issued, will provide Harvard additional intellectual property protection to support the development and commercialization by DNAPrint of new diagnostic tests to better define and manage diabetes more effectively.
The studies conducted by Dr. Halperin and his Harvard Medical School colleagues indicate that CD59 becomes inactivated in the presence of high blood glucose levels observed in patients with diabetes, and thus does not function normally to protect blood vessel walls from inflammatory damage. This leads to the obstruction of the many small vessels that provide critical nutrients and oxygen to organs and tissues. The common vascular disease complications suffered by individuals with diabetes -- nephropathy, retinopathy, neuropathy and atherosclerotic heart disease -- are all believed to be caused by this vascular obstruction and destruction. A test to detect CD59 in its glycated, inactive form would be a specific warning that the patient has had poor glucose control and that vascular complications are developing even before clinical symptoms show irreversible tissue and organ damage.
"Microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries are major reasons why medical costs are so high for patients with diabetes as well as causing unfortunate suffering for this group of patients of all ages," commented DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc. "Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar or glucose levels experienced by even well-controlled diabetes patients. Now we are able to move forward confidently with the development of our test, knowing that we have appropriate patent protection."
"Approval of the latest patent claims represents a milestone for Dr. Jose Halperin of Harvard Medical School and his team," commented DNA Print President and Chief Executive Officer Richard Gabriel. "According to the Center for Disease Control and Prevention, the total direct and indirect cost for both type 1 and type 2 diabetes in the United States in 2002 (four years ago) was $132 billion. Our goal is to try to help patients with diabetes understand their disease earlier, and with this knowledge, attempt to minimize their physical complications as well as reduce the associated expense to the U.S. healthcare system. We also know from physician reports that diabetes is expressed more in some patient population groups than others, so coupling our new CD59 diagnostic with our genetic ancestry information will be a valuable tool in developing and understanding the CD59 diagnostic," he concluded.
Details about the field-exclusive licensing agreement between DNAPrint Genomics, Inc. and Harvard University announced on January 26, 2006 can be found at:
http://www.dnaprint.com/welcome/press/press_recent/2006/0126/ DNAG-HARVARD.pdf
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
Kind of spinning wheels right now. I hope it takes off.
Some bedtime thoughts for the team: For a risky buy if you want to throw some cash at it----FLIP. .05 or less is good.
I still like ATVE under .12---if it goes to .10 or under then mortgage the house and load up.
See everyone in the morning.
Holding the line---ready to spend---keeping eyes open.
Yes, the bball hurts today.
Late getting into office. Trouble getting computer going---and that never happens to me?? Rolled in on fumes today.
It's Monday. All that adds up to misses in the penny world. Holding GWGO--not sure how long. Oh yea, I need to get some work done as well. Favorite bakery closed on Monday's so no good snacks here. I NEED TO START OVER !!!!
Glad you all are making money.
I'm off to a slow start today. Bummer, because I could not wait for Monday to get here. Cash just sitting around.
Is the GWGO party over?
Interesting. How do you see that trade?
Anyone have a chart on GWGO. How long are we holding? I have to be at the golf course in one hour!! Decisions, decisions.
Hope you all have your GWGO !!!!!!
The previous is a bold prediction, but I thought it was worth passing on.
Stock Winner
Stock Winner PicksDisclaimer
The Stock Winner helps investors win at investing in stocks that are undervalued or poised to run. We're here to help build your portfolio. Stock Winner believes in a well rounded portfolio. We've given the green light on SIRI, GOAM, BGO, RGLD, KB, BKYI, ADMH and CKXE formerly SPEA. Look at the 6 month and 1 year charts. BOOKMARK this page for updates.
At The Stock Winner, we're focusing on undervalued stocks that we feel will return large profits within weeks and will help build a strong, long term portfolio. The information provided will help you make a wise investment decision. Stock Winner owns shares in every pick it makes.
HOT PICK!! = GTEC.OB
Genesis Technology Group Inc.
Ticker Symbol: GTEC.OB
Feb. 27th Pick Price: 0.175
Current Price: 0.255 -0.006 (+2.41%)
Short Term Target Price: $0.75
Long Term Target Price: $1.50
Shares Outstanding: 71,000,000
Market Cap: 18.32 Million
Got it. Thanks. As an avid golfer I am surprised this company has not taken off better than it has.
What is all the hype with WGFL? I see nothing new
Where is the morning buy?
No news and I see its moving???
Chicken
I'm Freaking out!!!!!
86 percent today !!!!
How high can this thing go?
Do we sell today?
How is your chart looking?
I am getting nothing done in the office I watch this thing fly. GO USXP
Wow--hope you are correct.
Holy Cow--I'm glad I broke my own rule. Where is Stocks4O. She is missing the fun.
I am bracking a cardinal rule and chasing it! I usually get burned for this but what the heck.
dumb me got out yesterday. Oh well, made some money.
Keep an eye on things O baby. I am leaving to grab a fast lunch.
Wow, I am impressed. A good customer for sure.